Osterweis Capital Management Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 20.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,455 shares of the medical research company's stock after purchasing an additional 13,169 shares during the period. Thermo Fisher Scientific accounts for about 0.0% of Osterweis Capital Management Inc.'s holdings, making the stock its 27th biggest position. Osterweis Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $38,542,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors also recently bought and sold shares of the business. Banco BTG Pactual S.A. acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $415,000. Dorsey & Whitney Trust CO LLC grew its stake in shares of Thermo Fisher Scientific by 12.2% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 5,162 shares of the medical research company's stock valued at $2,569,000 after buying an additional 560 shares during the period. Breed s Hill Capital LLC grew its stake in shares of Thermo Fisher Scientific by 16.9% during the 1st quarter. Breed s Hill Capital LLC now owns 818 shares of the medical research company's stock valued at $407,000 after buying an additional 118 shares during the period. Capital Analysts LLC grew its stake in shares of Thermo Fisher Scientific by 9.7% during the 1st quarter. Capital Analysts LLC now owns 6,735 shares of the medical research company's stock valued at $3,352,000 after buying an additional 598 shares during the period. Finally, Tradition Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 10.2% during the 1st quarter. Tradition Wealth Management LLC now owns 1,323 shares of the medical research company's stock valued at $658,000 after buying an additional 122 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently issued reports on TMO shares. Royal Bank Of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. HSBC reaffirmed a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Evercore ISI decreased their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.
View Our Latest Stock Report on TMO
Thermo Fisher Scientific Stock Performance
Shares of Thermo Fisher Scientific stock opened at $497.9350 on Wednesday. The firm has a market cap of $188.03 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 2.60 and a beta of 0.74. The firm's 50-day simple moving average is $438.09 and its 200-day simple moving average is $458.53. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.
Insider Transactions at Thermo Fisher Scientific
In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $52,037,916.68. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,400 shares of company stock worth $8,345,792 in the last three months. 0.33% of the stock is currently owned by corporate insiders.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
MarketBeat All Access